ES2139759T3 - Antagonistas de citoquina. - Google Patents

Antagonistas de citoquina.

Info

Publication number
ES2139759T3
ES2139759T3 ES94930818T ES94930818T ES2139759T3 ES 2139759 T3 ES2139759 T3 ES 2139759T3 ES 94930818 T ES94930818 T ES 94930818T ES 94930818 T ES94930818 T ES 94930818T ES 2139759 T3 ES2139759 T3 ES 2139759T3
Authority
ES
Spain
Prior art keywords
cytokine antagonists
receptor component
antagonsists
cntf
extracellular domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94930818T
Other languages
English (en)
Other versions
ES2139759T5 (es
Inventor
Neil Stahl
Economides
George D Yancopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22490270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2139759(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2139759T3 publication Critical patent/ES2139759T3/es
Publication of ES2139759T5 publication Critical patent/ES2139759T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEINAS HETERODIMERICAS QUE COMPRENDEN UNA ESPECIFICIDAD {AL} SOLUBLE QUE DETERMINA UN COMPONENTE RECEPTOR DE LA CITOQUINA, Y EL DOMINIO EXTRACELULAR DE UN COMPONENTE {BE}-RECEPTOR Y QUE FUNCIONAN COMO ANTAGONISTAS DEL CNTF Y DE IL-6.
ES94930818T 1993-10-20 1994-10-19 Antagonistas de citoquina. Expired - Lifetime ES2139759T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US140222 1993-10-20
US08/140,222 US5470952A (en) 1993-10-20 1993-10-20 CNTF and IL-6 antagonists

Publications (2)

Publication Number Publication Date
ES2139759T3 true ES2139759T3 (es) 2000-02-16
ES2139759T5 ES2139759T5 (es) 2007-11-16

Family

ID=22490270

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94930818T Expired - Lifetime ES2139759T5 (es) 1993-10-20 1994-10-19 Antagonistas de citoquina.

Country Status (15)

Country Link
US (2) US5470952A (es)
EP (1) EP0726954B2 (es)
JP (1) JP3961562B2 (es)
CN (1) CN1138350A (es)
AT (1) ATE187982T1 (es)
AU (1) AU679579B2 (es)
CA (1) CA2173846C (es)
DE (1) DE69422304T3 (es)
DK (1) DK0726954T4 (es)
ES (1) ES2139759T5 (es)
GR (1) GR3032777T3 (es)
IL (1) IL111324A0 (es)
PT (1) PT726954E (es)
WO (1) WO1995011303A1 (es)
ZA (1) ZA948242B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
IT1261787B (it) * 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
AUPN024994A0 (en) * 1994-12-23 1995-01-27 Ludwig Institute For Cancer Research Assay and peptides for use therein
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
IT1288388B1 (it) 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
US6046158A (en) * 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
SE9701010D0 (sv) * 1997-03-19 1997-03-19 Pharmacia & Upjohn Ab Antibody
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
ES2226335T3 (es) 1998-01-23 2005-03-16 Immunex Corporation Receooctires de uk.18.
US6410245B1 (en) 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7083949B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6864359B1 (en) * 1999-02-11 2005-03-08 Xencor Structure-based screening techniques for drug discovery
EP1942114A3 (en) * 1999-03-11 2008-08-27 Schering Corporation Mammalian cytokines; related reagents and methods
US6800460B1 (en) 1999-03-11 2004-10-05 Schering Corporation Mammalian cytokine complexes
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
EP1221963A4 (en) * 1999-07-28 2006-03-22 Univ Pennsylvania METHODS FOR INHIBITING OSTEOCLASTOGENESIS
US6682739B1 (en) * 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
AU2002253942A1 (en) * 2001-02-12 2002-08-28 Michael Amling Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
US6864047B2 (en) 2001-03-29 2005-03-08 Mayo Foundation For Medical Education And Research IL1-β: a new target for myeloma therapy
WO2002088733A1 (fr) * 2001-04-23 2002-11-07 Eiken Kagaku Kabushiki Kaisha Methode d'analyse faisant intervenir une interaction intermoleculaire par rapporteur (marqueur)
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030143576A1 (en) * 2001-08-22 2003-07-31 Heman Chao Method and device for integrated protein expression, purification and detection
IL162269A0 (en) 2001-12-05 2005-11-20 Baylor College Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
US20060057145A1 (en) * 2002-10-25 2006-03-16 Government Of The United States Of America As Represented By The Secretary, Dept. Of Health Methods to prevent tumor recurrence by blockade of tgf-beta
FI20031050A7 (fi) * 2003-07-09 2005-01-10 Valtion Teknillinen Tutkimuskeskus Menetelmä proteiinien katkaisuun
WO2005033137A1 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7786261B2 (en) * 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007061981A2 (en) 2005-11-21 2007-05-31 Lumera Corporation Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
US7463358B2 (en) 2005-12-06 2008-12-09 Lumera Corporation Highly stable surface plasmon resonance plates, microarrays, and methods
WO2007079404A2 (en) * 2005-12-30 2007-07-12 Pharmaessentia Corp. Drug-polymer conjugates
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US8318135B2 (en) 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US8004669B1 (en) 2007-12-18 2011-08-23 Plexera Llc SPR apparatus with a high performance fluid delivery system
CA2737271C (en) * 2008-09-17 2020-06-23 National Research Council Of Canada Hetero-multivalent binding agents for members of the tgf.beta. superfamily
ES2780674T3 (es) 2012-11-15 2020-08-26 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
FI3359555T3 (fi) 2015-10-07 2024-03-20 Apellis Pharmaceuticals Inc Annostusohjeet
US11040107B2 (en) 2017-04-07 2021-06-22 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
BR112019021812A2 (pt) 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
CN110785431B (zh) 2017-05-04 2024-05-07 阿塞勒隆制药公司 TGF-β受体II型融合蛋白及其用途
WO2019118938A1 (en) 2017-12-15 2019-06-20 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2020086886A1 (en) 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JP3255699B2 (ja) * 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists

Also Published As

Publication number Publication date
CA2173846C (en) 2009-01-27
HK1008346A1 (en) 1999-05-07
EP0726954B2 (en) 2007-05-30
JPH09504030A (ja) 1997-04-22
JP3961562B2 (ja) 2007-08-22
DE69422304T2 (de) 2000-05-11
CA2173846A1 (en) 1995-04-27
DE69422304T3 (de) 2007-12-27
DK0726954T4 (da) 2007-10-01
WO1995011303A1 (en) 1995-04-27
US5470952A (en) 1995-11-28
EP0726954B1 (en) 1999-12-22
DE69422304D1 (de) 2000-01-27
GR3032777T3 (en) 2000-06-30
EP0726954A1 (en) 1996-08-21
CN1138350A (zh) 1996-12-18
ZA948242B (en) 1995-06-13
DK0726954T3 (da) 2000-05-01
AU679579B2 (en) 1997-07-03
AU7982794A (en) 1995-05-08
ES2139759T5 (es) 2007-11-16
US5844099A (en) 1998-12-01
IL111324A0 (en) 1994-12-29
ATE187982T1 (de) 2000-01-15
PT726954E (pt) 2000-04-28

Similar Documents

Publication Publication Date Title
ES2139759T3 (es) Antagonistas de citoquina.
ATE309375T1 (de) Onkostatin- m rezeptor
NO952398D0 (no) Pyrrolpyrimidiner som CRF antagonister
ATE401404T1 (de) Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
FI946005L (fi) Glysiinireseptoriantagonisteja ja niiden käyttö
MY108579A (en) Endothelin receptor antagonists
EP0667773A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS.
FI961804A7 (fi) Endoteliinireseptoriantagonistit
LV11460A (lv) Estrogenu agonisti un antagonisti
FI941178A7 (fi) 5-HT4-reseptoriantagonisteja
GR1001129B (el) Ανταγωνιστες ccκ αναλογου αμινοξεος.
ES2172535T3 (es) Antagonistas de los receptores de la endotelina.
FI933253A7 (fi) Uusia amyliiniantagonistipeptidejä ja käyttö amyliiniantagonisteina
ES2190487T3 (es) Nuevos agonistas y antagonistas del receptor de adenosina a1.
RU94044322A (ru) Замещенные в кольце z-амино-1,2,3,4-тетрагидронафталины и 3-аминохроманы
MX9606179A (es) Agonistas y antagonistas de los receptores del acido acetilcolina nicotinico de insectos para el control de endoparasitos.
BR9408265A (pt) Antagonistas de receptor de c5a não tendo substancialmente nenhuma atividade de antagonista
ES2165020T3 (es) Monohidrato de famciclovir.
FI922346A7 (fi) Muscarinreceptorantagonister.
IT1284524B1 (it) Uso di proteine come agenti anti-retrovirali
MX9203582A (es) Peptidos y composiciones farmaceuticas con actividad agonista y antagonista de la hormona de glicoproteina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 726954

Country of ref document: ES